● Recruiting

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Condition: Metastatic Uveal Melanoma · Sponsor: Replimune, Inc.

PhasePhase 2/Phase 3

Planned participants280

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials at Replimune · 1-781-222-9570 · Clinicaltrials@replimune.com

Giuseppe Gullo, MD

Always discuss trial participation with your own doctor first.

Locations (33)

HonorHealth Research Insisute	Scottsdale, Arizona, United States	Recruiting
UC San Diego Moores Cancer Center	La Jolla, California, United States	Recruiting
The Angeles Clinic and Research Institute	Los Angeles, California, United States	Recruiting
University of California Los Angeles	Los Angeles, California, United States	Recruiting
Stanford Cancer Institute	Palo Alto, California, United States	Recruiting
University of Colorado Hospital - Anschutz Cancer Pavilion(ACP)	Aurora, Colorado, United States	Recruiting
The Melanoma & Skin Cancer Institute	Englewood, Colorado, United States	Recruiting
Georgetown University Medical Center	Washington D.C., District of Columbia, United States	Recruiting
Mayo Clinic - Jacksonville FL	Jacksonville, Florida, United States	Recruiting
Sylvester Comprehensive Cancer Center	Miami, Florida, United States	Recruiting
Emory Winship Cancer Institute	Atlanta, Georgia, United States	Recruiting
Northwestern Memorial Hospital	Chicago, Illinois, United States	Recruiting

+ 21 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06581406